Abstract: Bioprosthetic components based on, or comprising, biological materials for implants, preferably biological heart valves, in particular biological heart valve leaflets, which have only been chemically or thermally stabilized (partly crosslinked) at mechanically stressed points and therefore have zones having different mechanical properties, and to a method for the production thereof.

Abstract: An embodiment of the present invention relates to a balloon catheter, which has a drug-releasing coating and/or cavity filling on at least parts of the outwardly facing surface of the dilatable balloon, characterized in that the coating comprises a drug and a gelatin mixture, the gelatin components of the gelatin mixture comprising 10-90 wt. % high-bloom gelatin having a gel strength of ?250 bloom and 90-10 wt. % medium-bloom gelatin having a gel strength of ?50 to <250 bloom, the specifications in wt. % relating to the total weight of the gelatin components of the gelatin mixture.

Abstract: One embodiment of the invention concerns a medical implant having a basic body that includes the antioxidative substance squalene incorporated into at least one of the basic body and a coating on at least a portion of the basic body, the incorporated squalene being present in quantities of 0.4 ?g to 2000 ?g.

Abstract: Various embodiments of the invention relate to a cRGD peptide derivative and an associated manufacturing method, and to an implant having a coating containing a cRGD peptide derivative. One aspect of the invention is the provision of a cRGD peptide derivative having the formula (1): wherein x=0-8, in particular 4-8, and R is a hydrophobic group.

Abstract: Some embodiments of the present invention relate to coated biological material for the manufacture of heart valve prostheses, characterized in that the surface of the biological material is covered entirely or partially with a coating which contains or is composed of a biocompatible anorganic material, and to a process for manufacturing such a coated biological material.

Abstract: The invention relates to an implantation device (10a-d) comprising at least one medical implant (12a-d) and at least one implantation aid (14a-d) comprising at least one expansion element (16a-d). It is provided that the expansion element (16a-d) can be inserted into at least one cavity (18a-d) of the implant (12a-d), and the at least one cavity (18a-d) can be expanded using the expansion element (16a-d), and, in the end state, the expansion element (16a-d) is disposed at least partially in the at least one cavity (18a-d), wherein the expansion element (16a-d) is designed as a solid body (20a-d).

Abstract: The invention relates to a medical valve implant (10a-d), in particular a heart valve implant (12a-d), for implantation in an animal body and/or human body, comprising a support frame (14a-d) which has at least one wall (16a-d). It is provided that one region (18a-d) of the at least one wall (16a-d) of the support frame (14a-d) is curable.

Abstract: The present invention relates to an implant (10), and particularly to an intraluminal endoprosthesis, comprising a body and at least one abluminal layer (3) disposed on the body, the abluminal layer preferably containing at least one pharmaceutically active substance. In order to protect the abluminal layer (3) from delamination or shearing, the abluminal layer (3) is additionally fastened to the implant body at least in a transition region (7) by way of at least one anchoring layer (5) disposed on the abluminal layer (3). In addition, methods for producing such an implant are described.

Abstract: The invention relates to a stent, comprising or consisting of amorphous polylactide. The invention relates further to the use of amorphous polylactide for stabilizing a stent and a method for producing a corresponding stent.

Abstract: The invention relates to an implant comprising an active-agent-containing coating which covers the implant at least in sections. The coating is composed of at least two subsections; a first subsection contains the at least one active substance, and a second subsection contains an auxiliary agent.

Abstract: At least some embodiments of the invention relates to an implant having a coating that contains or is composed of a functionalized RGD peptidomimetic RGD-P1 having the formula (1) and/or a functionalized RGD peptidomimetic RGD-P2 having the formula (2), and an associated manufacturing method.

Abstract: A theranostic article has one or more specific molecular recognition markers for cells on the surface thereof, wherein the recognition markers are selected from the group consisting of peptides, proteins, antibodies, antigens, aptamers, molecular imprinted polymers and polynucleotides. When the article is implanted in a body, cellular ingrowth is controlled, with desired cell types anchoring and proliferating on the implant's surface to generate a thin layer, and thereafter ceasing accumulation. The cellular layer thereby presents a biomimetic surface acceptable to the body, and also presents a low barrier to diffusion of analytes with at least substantially constant diffusion characteristics, allowing use of an analyte sensor within the article.

Abstract: Various embodiments of the invention relate to a cRGD peptide derivative and an associated manufacturing method, and to an implant having a coating containing a cRGD peptide derivative. One aspect of the invention is the provision of a cRGD peptide derivative having the formula (1): wherein x=0-8, in particular 4-8, and R is a hydrophobic group.

Abstract: At least some embodiments of the invention relates to an implant having a coating that contains or is composed of a functionalized RGD peptidomimetic RGD-P1 having the formula (1) and/or a functionalized RGD peptidomimetic RGD-P2 having the formula (2), and an associated manufacturing method.

Abstract: The invention concerns methods of coating stents and stents produced in accordance therewith. The object of the invention is to provide methods of coating stents with a polysaccharide layer which has improved adhesion capacity on the substrate surface of the implant, and to afford correspondingly functionalized stents. That is achieved inter alia by covalent bonding of a non-crosslinked hyaluronic acid to a substrate surface of the stent with the formation of hyaluronic acid layer and crosslinking of the hyaluronic acid layer.

Abstract: One embodiment of the invention relates to a coated implant having a base body composed of a biocorrodible magnesium alloy. The coating of the implant comprises: (i) a base layer, which is applied to the base body, composed of a basic polymer having a repeater unit that contains units of formula (1) or (2) and (ii) a polymeric cover layer that is applied directly to the base layer.

Abstract: A medical implant (10), and particularly to a valve implant (12), for implantation in an animal and/or human body (14), comprising a base body (16) which can be expanded at least in some regions. It is proposed that the base body (16) which can be expanded at least in some regions comprises a first actively expandable region (18) and at least one second passively expandable region (20, 22).

Abstract: The present invention refers to an implant with a surface layer having a topographic modification. The topographic modification includes a line pattern with ridge and groove widths of 0.9 to 1.1 ?m and a ridge height of more than 0.9 ?m.

Abstract: Some invention embodiments relate to an implant having a base body composed of a biocorrodible magnesium alloy and a polylactide coating. The implant is characterized in that the coating contains seed crystals and/or lipophilic substances as additives.

Abstract: A drug-eluting stent, comprising a base body that is made of an implant material, the base body being partially or entirely covered on the abluminal side with an active ingredient-releasing coating that comprises or is made of a polymer and an active ingredient having an antiproliferative effect, characterized in that the stent's luminal surface and the abluminal surface carrying the active ingredient-releasing coating are covered by a biocorrodible protective layer in a form-fitting manner.